<DOC>
	<DOCNO>NCT00106548</DOCNO>
	<brief_summary>This 3 arm study compare safety efficacy , regard reduction sign symptom , tocilizumab versus placebo , combination methotrexate ( MTX ) . patient moderate severe active rheumatoid arthritis ( RA ) currently inadequate response MTX . Patients wil randomized receive tocilizumab 4mg/kg iv , tocilizumab 8mg/mg iv , placebo iv , every 4 week ; patient also receive methotrexate 10-25mg weekly . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Assess Effect Tocilizumab + Methotrexate Signs Symptoms Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient least 18 year age moderate severe active RA least 6 month ; inadequate response stable dose MTX ; patient reproductive potential must use reliable method contraception . major surgery ( include joint surgery ) within 8 week enter study , plan surgery within 6 month enter study ; prior treatment failure antitumor necrosis factor agent ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>